1. Home
  2. NKTR vs LUNG Comparison

NKTR vs LUNG Comparison

Compare NKTR & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKTR
  • LUNG
  • Stock Information
  • Founded
  • NKTR 1990
  • LUNG 1995
  • Country
  • NKTR United States
  • LUNG United States
  • Employees
  • NKTR N/A
  • LUNG N/A
  • Industry
  • NKTR Biotechnology: Pharmaceutical Preparations
  • LUNG Industrial Specialties
  • Sector
  • NKTR Health Care
  • LUNG Health Care
  • Exchange
  • NKTR Nasdaq
  • LUNG Nasdaq
  • Market Cap
  • NKTR 247.9M
  • LUNG 251.5M
  • IPO Year
  • NKTR 1994
  • LUNG 2020
  • Fundamental
  • Price
  • NKTR $0.93
  • LUNG $6.23
  • Analyst Decision
  • NKTR Buy
  • LUNG Buy
  • Analyst Count
  • NKTR 3
  • LUNG 6
  • Target Price
  • NKTR $4.00
  • LUNG $11.92
  • AVG Volume (30 Days)
  • NKTR 2.2M
  • LUNG 242.6K
  • Earning Date
  • NKTR 11-07-2024
  • LUNG 02-19-2025
  • Dividend Yield
  • NKTR N/A
  • LUNG N/A
  • EPS Growth
  • NKTR N/A
  • LUNG N/A
  • EPS
  • NKTR N/A
  • LUNG N/A
  • Revenue
  • NKTR $93,137,000.00
  • LUNG $79,302,000.00
  • Revenue This Year
  • NKTR $12.85
  • LUNG $22.26
  • Revenue Next Year
  • NKTR N/A
  • LUNG $18.72
  • P/E Ratio
  • NKTR N/A
  • LUNG N/A
  • Revenue Growth
  • NKTR 5.53
  • LUNG 22.34
  • 52 Week Low
  • NKTR $0.47
  • LUNG $5.46
  • 52 Week High
  • NKTR $1.93
  • LUNG $14.84
  • Technical
  • Relative Strength Index (RSI)
  • NKTR 33.04
  • LUNG 41.37
  • Support Level
  • NKTR $0.89
  • LUNG $5.72
  • Resistance Level
  • NKTR $1.04
  • LUNG $6.28
  • Average True Range (ATR)
  • NKTR 0.07
  • LUNG 0.40
  • MACD
  • NKTR -0.00
  • LUNG -0.03
  • Stochastic Oscillator
  • NKTR 14.81
  • LUNG 19.85

About NKTR Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: